All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMG-20
Therapeutic Area: Dermatology Product Name: IMG-20
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Ventures
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2020
Details:
The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials for multiple indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
CBP-201 is a potent monoclonal antibody against IL-4Rα. Data support further evaluation of CBP-201’s effects in an ongoing dose-ranging study in patients with moderate-to-severe AD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SHR0302
Therapeutic Area: Dermatology Product Name: SHR0302
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
The study conducted in ten sites in Australia and New Zealand, evaluated the efficacy and safety of CBP-201 in 31 patients with moderate-to-severe AD who have had inadequate response to topical corticosteroids and immunosuppressants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2020
Details:
The company plans to use the proceeds to support the ongoing Phase 2 clinical trial for CBP-201; Phase 2 trials of CBP-307; expand the CBP-201 clinical development program into additional indications; and to support planned Phase 3 trials of CBP-201 and CBP-307.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.